High NOTCH1 expression is significantly associated with longer overall survival with the addition of an anti–PD-L1 inhibitor to first-line chemotherapy among NE subsets of extensive-stage SCLC patients. The gene discussed is NOTCH1; the disease is small cell lung carcinoma.